Wei Yuan Synthesis Closes Series B to Build the Open Platform Layer for AI-Powered Synthetic Biology ### What This Round Actually Signals When a company operating at the intersection of artificial intelligence and synthetic biology closes a Series B — even at a size of 43,350,300 CNY (≈$6.1 million) — it is rarely just about the money. It is about timing and conviction. The raise by Wei Yuan Synthesis, announced on 31 March 2026, reflects a specific thesis gaining traction in China's deep tech ecosystem: that the next frontier of biological computing will not be won by closed, proprietary labs working in isolation, but by open collaboration platforms that let distributed scientific communities build on shared infrastructure. This is a meaningful distinction. The bet here is not simply that AI can accelerate drug discovery or protein folding — ground already well-trodden by larger players globally. The bet is that…